Cerus Corporation Cash Flow Conversion Efficiency
Cerus Corporation cash flow conversion efficiency. Based on the latest financial reports, Cerus Corporation (CERS) has a cash flow conversion efficiency ratio of -0.045x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-3.05 Million) by net assets ($68.29 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Cerus Corporation (1997–2025)
Cash flow conversion efficiency of Cerus Corporation from 1997 to 2025. This chart illustrates how Cerus Corporation's cash flow conversion efficiency has evolved over time, based on yearly financial data. View current stock price of Cerus Corporation for real-time trading data and today's change.
Cerus Corporation Cash Flow Conversion Ratio Explained
Cerus Corporation cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Cerus Corporation Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Cerus Corporation ranked by their cash flow conversion efficiency. Also see Cerus Corporation market cap and net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Semco Technologies Sas
PA:ALSEM
|
N/A |
|
Evolus Inc
NASDAQ:EOLS
|
0.116x |
|
Aquestive Therapeutics Inc
NASDAQ:AQST
|
0.435x |
|
B+S GROUP SA INH EO-06
F:70B
|
N/A |
|
Regenxbio Inc
NASDAQ:RGNX
|
-0.867x |
|
Aberdeen Standard Global Infrastructure Income Fund
NYSE:ASGI
|
N/A |
|
COINSHARES I. LS-000247
F:3TW
|
-0.162x |
|
Jee Technology Co. Ltd. A
SHG:688162
|
N/A |
Annual Cash Flow Conversion Efficiency for Cerus Corporation (1997–2025)
The table below shows the annual cash flow conversion efficiency of Cerus Corporation from 1997 to 2025. Review CERS free cash flow to operating cash ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $64.97 Million | $11.36 Million | 0.175x | -12.42% |
| 2024-12-31 | $56.90 Million | $11.36 Million | 0.200x | +124.72% |
| 2023-12-31 | $53.44 Million | $-43.17 Million | -0.808x | -116.20% |
| 2022-12-31 | $68.56 Million | $-25.61 Million | -0.374x | +5.70% |
| 2021-12-31 | $85.62 Million | $-33.92 Million | -0.396x | +1.63% |
| 2020-12-31 | $103.81 Million | $-41.81 Million | -0.403x | +64.92% |
| 2019-12-31 | $57.05 Million | $-65.50 Million | -1.148x | -210.54% |
| 2018-12-31 | $84.52 Million | $-31.25 Million | -0.370x | +72.44% |
| 2017-12-31 | $38.94 Million | $-52.23 Million | -1.341x | -44.81% |
| 2016-12-31 | $57.79 Million | $-53.53 Million | -0.926x | -71.69% |
| 2015-12-31 | $94.77 Million | $-51.13 Million | -0.540x | +43.47% |
| 2014-12-31 | $41.71 Million | $-39.81 Million | -0.954x | -52.43% |
| 2013-12-31 | $42.80 Million | $-26.80 Million | -0.626x | +14.03% |
| 2012-12-31 | $19.11 Million | $-13.92 Million | -0.728x | +14.67% |
| 2011-12-31 | $18.31 Million | $-15.63 Million | -0.854x | -43.56% |
| 2010-12-31 | $23.73 Million | $-14.11 Million | -0.595x | +13.03% |
| 2009-12-31 | $21.45 Million | $-14.66 Million | -0.684x | +32.16% |
| 2008-12-31 | $34.28 Million | $-34.55 Million | -1.008x | -61.36% |
| 2007-12-31 | $59.89 Million | $-37.40 Million | -0.625x | -329.42% |
| 2006-12-31 | $100.97 Million | $-14.69 Million | -0.145x | +65.68% |
| 2005-12-31 | $35.27 Million | $-14.95 Million | -0.424x | +28.46% |
| 2004-12-31 | $21.49 Million | $-12.73 Million | -0.592x | +46.92% |
| 2003-12-31 | $52.53 Million | $-58.62 Million | -1.116x | -12.62% |
| 2002-12-31 | $56.17 Million | $-55.65 Million | -0.991x | -140.40% |
| 2001-12-31 | $106.75 Million | $-44.00 Million | -0.412x | -5.41% |
| 2000-12-31 | $81.92 Million | $-32.03 Million | -0.391x | +61.25% |
| 1999-12-31 | $33.00 Million | $-33.30 Million | -1.009x | +86.48% |
| 1998-12-31 | $1.30 Million | $-9.70 Million | -7.462x | -911.35% |
| 1997-12-31 | $22.50 Million | $-16.60 Million | -0.738x | -- |
About Cerus Corporation
Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The company offers INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company also offer… Read more